BPG is committed to discovery and dissemination of knowledge
Articles Published Processes Featured Articles Journals Submit a Manuscript
Cited by in CrossRef
For: Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol 2015; 21(22): 6820-6834 [PMID: 26078558 DOI: 10.3748/wjg.v21.i22.6820]
URL: https://www.wjgnet.com/1007-9327/full/v21/i22/6820.htm
(387) (365) (0) (0) (13319) (110)
Number Citing Articles
1
Qian Li, Manish Dhyani, Joseph R Grajo, Claude Sirlin, Anthony E Samir. Current status of imaging in nonalcoholic fatty liver disease. World Journal of Hepatology 2018; 10(8): 530-542 doi: 10.4254/wjh.v10.i8.530
2
Eider Talavera-Urquijo, Sarai Rodríguez-Navarro, Marc Beisani, Maria Teresa Salcedo-Allende, Aisha Chakkur, Marc Arús-Avilés, Manel Cremades, Salvador Augustin, María Martell, José M. Balibrea. Morphofunctional Changes After Sleeve Gastrectomy and Very Low Calorie Diet in an Animal Model of Non-Alcoholic Fatty Liver Disease. Obesity Surgery 2018; 28(1) doi: 10.1007/s11695-017-2805-4
3
Alex Benjamin, Rebecca Zubajlo, Kai Thomenius, Manish Dhyani, Kanakaraju Kaliannan, Anthony E. Samir, Brian W. Anthony. Non-invasive diagnosis of non-alcoholic fatty liver disease (NAFLD) using ultrasound image echogenicity. 2017 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) 2017;  doi: 10.1109/EMBC.2017.8037468
4
Niki Katsiki, Athanasios D Giannoukas, Vasilios G Athyros, Dimitri P Mikhailidis. Lipid-lowering treatment in peripheral artery disease. Current Opinion in Pharmacology 2018; 39 doi: 10.1016/j.coph.2018.01.003
5
Arthur Balestra Silveira Ayres, Carollyne Rodovalho Guerra Carneiro, Martinho Antonio Gestic, Murillo Pimentel Utrini, Felipe David Mendonça Chaim, Francisco Callejas-Neto, Elinton Adami Chaim, Everton Cazzo. Identification of Predictors of Non-alcoholic Steatohepatitis and Its Severity in Individuals Undergoing Bariatric Surgery. Obesity Surgery 2024; 34(2) doi: 10.1007/s11695-023-06986-5
6
Konstantinos P. Imprialos, Konstantinos Stavropoulos, Michael Doumas, Anastasia Skalkou, Ioanna Zografou, Vasilios G. Athyros. The potential role of statins in treating liver disease. Expert Review of Gastroenterology & Hepatology 2018; 12(4) doi: 10.1080/17474124.2018.1439379
7
Adriana Sánchez-García, Amirhossein Sahebkar, Mario Simental-Mendía, Luis E. Simental-Mendía. Effect of ursodeoxycholic acid on glycemic markers: A systematic review and meta-analysis of clinical trials. Pharmacological Research 2018; 135 doi: 10.1016/j.phrs.2018.08.008
8
I. V. Logacheva, T. A. Ryazanova, V. R. Makarova, O. V. Surnina. Non-Alcoholic Fatty Liver Disease in Cardiac Patients with Overweight and Obesity. Russian Journal of Gastroenterology, Hepatology, Coloproctology 2019; 28(6) doi: 10.22416/1382-4376-2018-28-6-27-37
9
Niki Katsiki, Anca Pantea Stoian, Paschalis Steiropoulos, Nikolaos Papanas, Andra-Iulia Suceveanu, Dimitri P. Mikhailidis. Metabolic Syndrome and Abnormal Peri-Organ or Intra-Organ Fat (APIFat) Deposition in Chronic Obstructive Pulmonary Disease: An Overview. Metabolites 2020; 10(11) doi: 10.3390/metabo10110465
10
M. Papagianni, K. Tziomalos. Non‐alcoholic fatty liver disease: an emerging predictor of stroke risk, severity and outcome. European Journal of Neurology 2018; 25(4) doi: 10.1111/ene.13584
11
Vasilios G. Athyros, Stergios A. Polyzos, Jiannis Kountouras, Niki Katsiki, Panagiotis Anagnostis, Michael Doumas, Christos S. Mantzoros. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. Current Vascular Pharmacology 2020; 18(2) doi: 10.2174/1570161117666190405164313
12
Vasilios G. Athyros, Niki Katsiki, Asterios Karagiannis, Dimitri P. Mikhailidis. Statins and non-alcoholic steatohepatitis. Journal of Hepatology 2016; 64(1) doi: 10.1016/j.jhep.2015.09.021
13
Shengjun Xiong, Pengbo Wang, Shizhang Yin, Wanshu Deng, Yuanhui Zhao, Wenhang Li, Zhao Li, Ying Zhou, Shasha Yu, Hongmei Yang, Xiaofan Guo, Yingxian Sun. The association between liver fibrosis scores and chronic kidney disease. Frontiers in Medicine 2023; 10 doi: 10.3389/fmed.2023.1046825
14
Niki Katsiki, Dimitri P. Mikhailidis, Christos S. Mantzoros. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism 2016; 65(8) doi: 10.1016/j.metabol.2016.05.003
15
Niki Katsiki, Vasilios G. Athyros, Asterios Karagiannis. Vildagliptin: any effect on non-alcoholic fatty liver disease and serum uric acid? Re: Shelbaya S, Rakha S. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt – results from the GUARD study. Curr Med Res Opin 2017;33:797-801. Current Medical Research and Opinion 2017; 33(12) doi: 10.1080/03007995.2017.1333955
16
Manorama Swain, Preetam Nath, Prasant Kumar Parida, Jimmy Narayan, Pradeep Kumar Padhi, Girish Kumar Pati, Ayaskanta Singh, Bijay Misra, Debasis Misra, Sanjib Kumar Kar, Manas Kumar Panigrahi, Chudamani Meher, Omprakash Agrawal, Niranjan Rout, Kaumudee Pattnaik, Pallavi Bhuyan, Pramila Kumari Mishra, Shivaram Prasad Singh. Biochemical Profile of Nonalcoholic Fatty Liver Disease Patients in Eastern India with Histopathological Correlation. Indian Journal of Clinical Biochemistry 2017; 32(3) doi: 10.1007/s12291-016-0612-7
17
Vasilios G. Athyros, Niki Katsiki, Dimitri P. Mikhailidis. Letter to the editor: Treating nonalcoholic fatty liver disease with statins. Are all statins equal?. American Journal of Physiology-Gastrointestinal and Liver Physiology 2017; 312(6) doi: 10.1152/ajpgi.00101.2017
18
Liat Mlynarsky, Dalit Schlesinger, Roni Lotan, Muriel Webb, Zamir Halpern, Erwin Santo, Oren Shibolet, Shira Zelber-Sagi. Non-alcoholic fatty liver disease is not associated with a lower health perception. World Journal of Gastroenterology 2016; 22(17): 4362-4372 doi: 10.3748/wjg.v22.i17.4362
19
Derek M. Erion, Hyun-Jun Park, Hui-Young Lee. The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities. BMB Reports 2016; 49(3) doi: 10.5483/BMBRep.2016.49.3.268
20
Takashi Kato, Man Hagiyama, Yasutoshi Takashima, Azusa Yoneshige, Akihiko Ito. Cell adhesion molecule-1 shedding induces apoptosis of renal epithelial cells and exacerbates human nephropathies. American Journal of Physiology-Renal Physiology 2018; 314(3) doi: 10.1152/ajprenal.00385.2017
21
Arrigo F. G. Cicero, Alessandro Colletti. An update on the safety of nutraceuticals and effects on lipid parameters. Expert Opinion on Drug Safety 2018; 17(3) doi: 10.1080/14740338.2018.1429404
22
Niki Katsiki, Anca Pantea Stoian, Manfredi Rizzo. Dietary patterns in non-alcoholic fatty liver disease (NAFLD): Stay on the straight and narrow path!. Clínica e Investigación en Arteriosclerosis (English Edition) 2022; 34 doi: 10.1016/j.artere.2022.07.002
23
Munehisa Bekki, Nobuhiro Tahara, Atsuko Tahara, Sachiyo Igata, Akihiro Honda, Yoichi Sugiyama, Tomohisa Nakamura, Jiahui Sun, Yuki Kumashiro, Takanori Matsui, Yoshihiro Fukumoto, Sho-ichi Yamagishi. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study. Current Vascular Pharmacology 2019; 17(4) doi: 10.2174/1570161116666180515154555
24
Kalliopi Pafili, Efstratios Maltezos, Nikolaos Papanas. Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 2016; 12(11) doi: 10.1080/17425255.2016.1229302
25
Alexios Giannakodimos, Evangelos Oikonomou, Panteleimon Pantelidis, Panagiotis Theofilis, Niki Katsiki, Athina Goliopoulou, Georgios E Zakynthinos, Emmanouil Korakas, Vasiliki Kalogera, Maciej Banach, Vaia Lampadiari, Eva Kassi, Ignatios Ikonomidis, Gerasimos Siasos. Arterial stiffness as a complication of metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. Expert Review of Gastroenterology & Hepatology 2025; 19(4) doi: 10.1080/17474124.2025.2471871
26
Sevket Balta. Atherosclerosis and Non-Alcoholic Fatty Liver Disease. Angiology 2022; 73(8) doi: 10.1177/00033197221091317
27
Omar Elshaarawy, Johannes Mueller, Sina Straub, Sebastian Mueller. Nicht-alkoholische Fettlebererkrankung. 2022;  doi: 10.1007/978-3-662-62484-5_13
28
TI Ledovskaya, ME Statsenko, SV Turkina, TA Konyakhina, KS Yusupov, EE Gorbacheva. Cardiovascular comorbidity in patients with nonalcoholic fatty liver disease. Medicine of Extreme Situations 2021; (2021(4)) doi: 10.47183/mes.2021.045
29
Niki Katsiki, Francesco Purrello, Costas Tsioufis, Dimitri P. Mikhailidis. Cardiovascular disease prevention strategies for type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 2017; 18(12) doi: 10.1080/14656566.2017.1351946
30
Cristiane Villela-Nogueira, Nathalie Leite, Claudia Cardoso, Gil Salles. NAFLD and Increased Aortic Stiffness: Parallel or Common Physiopathological Mechanisms?. International Journal of Molecular Sciences 2016; 17(4) doi: 10.3390/ijms17040460
31
Giovanna Muscogiuri, Ludovica Verde, Cem Sulu, Niki Katsiki, Maria Hassapidou, Evelyn Frias-Toral, Gabriela Cucalón, Agnieszka Pazderska, Volkan Demirhan Yumuk, Annamaria Colao, Luigi Barrea. Mediterranean Diet and Obesity-related Disorders: What is the Evidence?. Current Obesity Reports 2022; 11(4) doi: 10.1007/s13679-022-00481-1
32
Rosaria Vincenza Giglio, Angelo Maria Patti, Dragana Nikolic, Giovanni Li Volti, Khalid Al-Rasadi, Niki Katsiki, Dimitri P. Mikhailidis, Giuseppe Montalto, Ekaterina Ivanova, Alexander N. Orekhov, Manfredi Rizzo. The effect of bergamot on dyslipidemia. Phytomedicine 2016; 23(11) doi: 10.1016/j.phymed.2015.12.005
33
Niki Katsiki, Ele Ferrannini, Christos Mantzoros. New American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician's perspective. Metabolism 2020; 107 doi: 10.1016/j.metabol.2020.154218
34
Niki Katsiki, Anca Pantea Stoian, Manfredi Rizzo. Dietary patterns in non-alcoholic fatty liver disease (NAFLD): Stay on the straight and narrow path!. Clínica e Investigación en Arteriosclerosis 2022; 34 doi: 10.1016/j.arteri.2021.10.001
35
Erenius Toppo, S. Sylvester Darvin, S. Esakkimuthu, A. Stalin, K. Balakrishna, K. Sivasankaran, P. Pandikumar, S. Ignacimuthu, N.A. Al-Dhabi. Antihyperlipidemic and hepatoprotective effects of Gardenin A in cellular and high fat diet fed rodent models. Chemico-Biological Interactions 2017; 269 doi: 10.1016/j.cbi.2017.03.013
36
Niki Katsiki, Michael Doumas, Vasilios Athyros. Metabolic syndrome: joint diagnostic criteria and links with comorbidities. Hormones 2019; 18(1) doi: 10.1007/s42000-018-0074-9
37
Kaveh Hajifathalian, Zaid Tafesh, Russell Rosenblatt, Sonal Kumar, Edwin A. Homan, Reem Z. Sharaiha, David E. Cohen, Robert S. Brown, Brett E. Fortune. Effect of Statin Use on Cancer-related Mortality in Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology 2022; 56(2) doi: 10.1097/MCG.0000000000001503
38
Kalliopi Pafili, Manfredi Rizzo, Nikolaos Papanas. New antihyperglycaemic agents and cardiovascular disease. Current Opinion in Cardiology 2018; 33(4) doi: 10.1097/HCO.0000000000000524
39
Tetiana A. Trybrat, Yenhen Ye. Petrov, Svitlana V. Shut, Tetiana A. Ivanytska. The use of bischofite in comprehensive rehabilitation of patients with cardiovascular diseases and comorbid hepatobiliary pathology: current knowledge and future perspective. Acta Balneologica 2025;  doi: 10.36740/ABal202506113
40
Shabnam Radbakhsh, Niki Katsiki, Raul D. Santos, Dimitri P. Mikhailidis, Christos S. Mantzoros, Amirhossein Sahebkar. Effects of statins on specialized pro-resolving mediators: An additional pathway leading to resolution of inflammation. Metabolism 2022; 132 doi: 10.1016/j.metabol.2022.155211
41
Sadegh Mozaffari, Mahdeyeh Aliari, Solaleh Emamgholipour, Hossein Hosseini, Pedram Rezaei Amirkiasar, Mina Zare, Niki Katsiki, Ghodratollah Panahi, Amirhossein Sahebkar. The effect of probiotic consumption on lipid profile, glycemic index, inflammatory markers, and liver function in NAFLD patients: A systematic review and meta-analysis of randomized controlled trials. Journal of Diabetes and its Complications 2024; 38(8) doi: 10.1016/j.jdiacomp.2024.108780
42
Angelo Maria Patti, Rosaria Vincenza Giglio, Nikolaos Papanas, Manfredi Rizzo, Ali A. Rizvi. Future perspectives of the pharmacological management of diabetic dyslipidemia. Expert Review of Clinical Pharmacology 2019; 12(2) doi: 10.1080/17512433.2019.1567328
43
Pakkapon Rattanachaisit, Paweena Susantitaphong, Kessarin Thanapirom, Roongruedee Chaiteerakij, Piyawat Komolmit, Pisit Tangkijvanich, Sombat Treeprasertsuk. Statin use and histopathological change in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Asian Biomedicine 2018; 12(1) doi: 10.1515/abm-2018-0026
44
Mohsen Mazidi, Niki Katsiki, Dimitri P. Mikhailidis, Maciej Banach. Adiposity May Moderate the Link Between Choline Intake and Non-alcoholic Fatty Liver Disease. Journal of the American College of Nutrition 2019; 38(7) doi: 10.1080/07315724.2018.1507011
45
Laura J. Brattain, Brian A. Telfer, Manish Dhyani, Joseph R. Grajo, Anthony E. Samir. Objective Liver Fibrosis Estimation from Shear Wave Elastography. 2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) 2018;  doi: 10.1109/EMBC.2018.8513011
46
Morgan Marcuccilli, Michel Chonchol. NAFLD and Chronic Kidney Disease. International Journal of Molecular Sciences 2016; 17(4) doi: 10.3390/ijms17040562
47
Vasilios G. Athyros, Niki Katsiki, Michael Doumas. Lipid association of India (LAI) expert consensus statement: part 2, specific patient categories. Clinical Lipidology 2018; 13(1) doi: 10.1080/17584299.2017.1411068
48
Niki Katsiki, Genovefa Kolovou, Pablo Perez-Martinez, Dimitri P. Mikhailidis. Dyslipidaemia in the elderly: to treat or not to treat?. Expert Review of Clinical Pharmacology 2018; 11(3) doi: 10.1080/17512433.2018.1425138
49
Kívia De Andrade, Fabiana Moura, John Dos Santos, Orlando De Araújo, Juliana De Farias Santos, Marília Goulart. Oxidative Stress and Inflammation in Hepatic Diseases: Therapeutic Possibilities of N-Acetylcysteine. International Journal of Molecular Sciences 2015; 16(12) doi: 10.3390/ijms161226225
50
Georgios A. Christou, Niki Katsiki, John Blundell, Gema Fruhbeck, Dimitrios N. Kiortsis. Semaglutide as a promising antiobesity drug. Obesity Reviews 2019; 20(6) doi: 10.1111/obr.12839
51
Rajkumar Chinnadurai, James Ritchie, Darren Green, Philip A Kalra. Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease. Nephrology Dialysis Transplantation 2019; 34(3) doi: 10.1093/ndt/gfx381
52
Tae Woo Jung, Hye Jin Yoo, Kyung Mook Choi. Implication of hepatokines in metabolic disorders and cardiovascular diseases. BBA Clinical 2016; 5 doi: 10.1016/j.bbacli.2016.03.002
53
Frank Tacke. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis. Expert Opinion on Investigational Drugs 2018; 27(3) doi: 10.1080/13543784.2018.1442436
54
Giuseppe Dattilo, Francesco Borgia, Claudio Guarneri, Matteo Casale, Roberto Bitto, Claudia Morabito, Salvatore Signorelli, Niki Katsiki, Serafinello P. Cannavò. Cardiovascular Risk in Psoriasis: Current State of the Art. Current Vascular Pharmacology 2018; 17(1) doi: 10.2174/1570161115666171116163816
55
Evangelos Chartampilas. Imaging of nonalcoholic fatty liver disease and its clinical utility. Hormones 2018; 17(1) doi: 10.1007/s42000-018-0012-x
56
I. V. Logacheva, T. A. Ryazanova, S. B. Ponomarev, V. R. Makarova. Multivariate prognosis of non-alcoholic fatty liver disease development in visceral obesity in patients with coronary artery disease and hypertension. Russian Journal of Cardiology 2021; 26(1) doi: 10.15829/1560-4071-2021-4015
57
Vasilios G. Athyros, Dimitri P. Mikhailidis. High incidence of metabolic syndrome further increases cardiovascular risk in patients with type 2 diabetes. Implications for everyday practice. Journal of Diabetes and its Complications 2016; 30(1) doi: 10.1016/j.jdiacomp.2015.07.012
58
Zoran Gluvic, Ratko Tomasevic, Ksenija Bojovic, Milan Obradovic, Esma R. Isenovic. Non-alcoholic fatty liver disease: a multidisciplinary clinical practice approach—the institutional adaptation to existing Clinical Practice Guidelines. Emergency and Critical Care Medicine 2022; 2(1) doi: 10.1097/EC9.0000000000000016
59
Simona Panunzi, Sabina Maltese, Ornella Verrastro, Luca Labbate, Andrea De Gaetano, Maurizio Pompili, Esmeralda Capristo, Stefan R. Bornstein, Geltrude Mingrone. Pioglitazone and bariatric surgery are the most effective treatments for non‐alcoholic steatohepatitis: A hierarchical network meta‐analysis. Diabetes, Obesity and Metabolism 2021; 23(4) doi: 10.1111/dom.14304
60
Hadi Emamat, Hossein Farhadnejad, Hossein Poustchi, Azita Hekmatdoost. Galactose intake is related to nonalcoholic fatty liver disease. Nutrition & Food Science 2019; 49(3) doi: 10.1108/NFS-06-2018-0174
61
Niki Katsiki, Nikolaos Perakakis, Christos Mantzoros. Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?. Metabolism 2019; 98 doi: 10.1016/j.metabol.2019.07.009
62
Simona Cernea, Avivit Cahn, Itamar Raz. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes. Expert Review of Clinical Pharmacology 2017; 10(5) doi: 10.1080/17512433.2017.1300059
63
Niki Katsiki, Dimitrios Tousoulis. Diabetes mellitus and comorbidities: A bad romance. Hellenic Journal of Cardiology 2020; 61(1) doi: 10.1016/j.hjc.2020.02.009
64
Kalliopi Pafili, Efstratios Maltezos, Nikolaos Papanas. Ipragliflozin and sodium glucose transporter 2 inhibitors to reduce liver fat: will the prize we sought be won?. Expert Opinion on Pharmacotherapy 2018; 19(3) doi: 10.1080/14656566.2017.1413346
65
Rebecca E. Zubajlo, Alex Benjamin, Joseph R. Grajo, Kanakaraju Kaliannan, Jing X. Kang, Atul K. Bhan, Kai E. Thomenius, Brian W. Anthony, Manish Dhyani, Anthony E. Samir. Experimental Validation of Longitudinal Speed of Sound Estimates in the Diagnosis of Hepatic Steatosis (Part II). Ultrasound in Medicine & Biology 2018; 44(12) doi: 10.1016/j.ultrasmedbio.2018.07.020
66
A. Yu. Timakova, Yu. P. Skirdenko, M. A. Livzan, T. S. Krolevets, N. A. Nikolaev, A. V. Nelidova. Cardiovascular comorbidity in non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology 2020; (10) doi: 10.31146/1682-8658-ecg-182-10-88-95
67
T. D. Filippatos, K. Alexakis, V. Mavrikaki, D. P. Mikhailidis. Nonalcoholic Fatty Pancreas Disease: Role in Metabolic Syndrome, “Prediabetes,” Diabetes and Atherosclerosis. Digestive Diseases and Sciences 2022; 67(1) doi: 10.1007/s10620-021-06824-7
68
Jie Han, Yong Wang, Zhongshang Yuan, Lu Liu, Meng Zhao, Qingbo Guan, Haiqing Zhang, Qiu Li, Jin Xu, Ling Gao, Jiajun Zhao, Xu Zhang. Nonalcoholic fatty liver disease represents a greater metabolic burden in patients with atherosclerosis. Medicine 2019; 98(11) doi: 10.1097/MD.0000000000014896
69
Tomas Vita, David J. Murphy, Michael T. Osborne, Navkaranbir S. Bajaj, Abhishek Keraliya, Sophia Jacob, Angel Joel Diaz Martinez, Ariana Nodoushani, Paco Bravo, Jon Hainer, Courtney F. Bibbo, Michael L. Steigner, Viviany R. Taqueti, Hicham Skali, Ron Blankstein, Marcelo F. Di Carli, Sharmila Dorbala. Association between Nonalcoholic Fatty Liver Disease at CT and Coronary Microvascular Dysfunction at Myocardial Perfusion PET/CT. Radiology 2019; 291(2) doi: 10.1148/radiol.2019181793
70
Manuela Abbate, Catalina M. Mascaró, Sofía Montemayor, Miguel Casares, Cristina Gómez, Lucia Ugarriza, Silvia Tejada, Itziar Abete, Maria Angeles Zulet, Antoni Sureda, J. Alfredo Martínez, Josep A. Tur. Non-Alcoholic Fatty Liver Disease Is Associated with Kidney Glomerular Hyperfiltration in Adults with Metabolic Syndrome. Journal of Clinical Medicine 2021; 10(8) doi: 10.3390/jcm10081717
71
Jelena Stevanović, Jorge Beleza, Pedro Coxito, António Ascensão, José Magalhães. Physical exercise and liver “fitness”: Role of mitochondrial function and epigenetics-related mechanisms in non-alcoholic fatty liver disease. Molecular Metabolism 2020; 32 doi: 10.1016/j.molmet.2019.11.015
72
Mustafa Koplay, Mustafa Gok, Mesut Sivri. The association between coronary artery disease and nonalcoholic fatty liver disease and noninvasive imaging methods. Electronic Journal of General Medicine 2019; 16(6) doi: 10.29333/ejgm/110689
73
Niki Katsiki, Vasilios G. Athyros, Dimitri P. Mikhailidis. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: Effects of statins and antidiabetic drugs. Journal of Diabetes and its Complications 2017; 31(3) doi: 10.1016/j.jdiacomp.2016.12.006
74
S. E. Evstifeeva, S. A. Shalnova, V. A. Kutsenko, А. V. Kapustina, G. A. Muromtseva, Yu. A. Balanova, A. E. Imaeva, N. S. Karamnova, M. B. Kotova, S. A. Maksimov, O. A. Litinskaya, M. S. Pokrovskaya, E. M. Filichkina, A. G. Soplenkova, L. I. Gomanova, O. B. Shvabskaya, Yu. Yu. Samokhina, I. A. Viktorova, N. N. Prishchepa, A. N. Redko, S. S. Yakushin, O. M. Drapkina. Fatty liver index as a predictor of fatal and non-fatal cardiovascular events in Russians: analysis of an epidemiological cohort. Cardiovascular Therapy and Prevention 2026; 24(12) doi: 10.15829/1728-8800-2025-4589
75
Jonathan J. Woolley, Jesse Fishman, Christina M. Parrinello, Tom O’Connell, Thomas Karlas. Cardiovascular risk in US adults with nonalcoholic steatohepatitis (NASH) vs. matched non-NASH controls, National Health and Nutrition Examination Survey, 2017–2020. PLOS ONE 2024; 19(8) doi: 10.1371/journal.pone.0309617
76
Niki Katsiki, George Dimitriadis, Dimitri P. Mikhailidis. Perirenal Adiposity and Other Excessive Intra- and Peri-Organ Fat Depots: What Is the Connection?. Angiology 2019; 70(7) doi: 10.1177/0003319719848204
77
Yu. M. Kazakov, Yu. I. Manusha, T. A. Trybrat, N. I. Chekalina, ’ S. V. Shut’. THE CLINICAL AND BIOCHEMICAL FEATURES OF LIVER‎’‎ FUNCTIONAL STATE IN PATIENTS WITH ISCHEMIC HEART DISEASE IN COMBINATION WITH NON-ALCOHOLIC FATTY LIVER DISEASE. Bulletin of Problems Biology and Medicine 2019; 3(152) doi: 10.29254/2077-4214-2019-3-152-118-121
78
Niki Katsiki, Genovefa Kolovou, Michal Vrablik. Metabolic Dysfunction Associated-Steatotic Liver Disease (MASLD) and Cardiovascular Risk: Embrace All Facets of the Disease. Current Cardiology Reports 2025; 27(1) doi: 10.1007/s11886-024-02181-9
79
Lucia Pacifico, Francesco Massimo Perla, Mario Roggini, Gianmarco Andreoli, Miriam D’Avanzo, Claudio Chiesa. A Systematic Review of NAFLD-Associated Extrahepatic Disorders in Youths. Journal of Clinical Medicine 2019; 8(6) doi: 10.3390/jcm8060868
80
Genovefa D. Kolovou, Gerald F. Watts, Dimitri P. Mikhailidis, Pablo Pérez-Martínez, Samia Mora, Helen Bilianou, George Panotopoulos, Niki Katsiki, Teik C. Ooi, José Lopez-Miranda, Anne Tybjærg-Hansen, Nicholas Tentolouris, Børge G. Nordestgaard. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. Current Vascular Pharmacology 2019; 17(5) doi: 10.2174/1570161117666190507110519
81
Theodora Griva, Chrysoula Boutari, Konstantinos Tziomalos, Michael Doumas, Asterios Karagiannis, Vasilios G. Athyros. Arterial Stiffness and Nonalcoholic Fatty Liver Disease: Which is the Chicken and Which is the Egg?. The Open Hypertension Journal 2017; 9(1) doi: 10.2174/1876526201709010001
82
Niki Katsiki, Dimitri P Mikhailidis, Maciej Banach. Leptin, cardiovascular diseases and type 2 diabetes mellitus. Acta Pharmacologica Sinica 2018; 39(7) doi: 10.1038/aps.2018.40
83
Arinc Ozturk, Ramin Mohammadi, Theodore T. Pierce, Sagar Kamarthi, Manish Dhyani, Joseph R. Grajo, Kathleen E. Corey, Raymond T. Chung, Atul K. Bhan, Jagpreet Chhatwal, Anthony E. Samir. Diagnostic Accuracy of Shear Wave Elastography as a Non-invasive Biomarker of High-Risk Non-alcoholic Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease. Ultrasound in Medicine & Biology 2020; 46(4) doi: 10.1016/j.ultrasmedbio.2019.12.020
84
Seyed Moayed Alavian, Hosein Zadi. The Relation Between Non-alcoholic Fatty Liver Disease and the Risk of Coronary Heart Disease. Multidisciplinary Cardiovascular Annals 2022; 13(1) doi: 10.5812/mca-121262
85
Niki Katsiki, Vasilios G Athyros. Non-alcoholic steatohepatitis and type 2 diabetes mellitus: the effects of weight loss versus drug treatment. Current Medical Research and Opinion 2019; 35(7) doi: 10.1080/03007995.2019.1589152
86
Niki Katsiki, Vasilios G. Athyros, Dimitri P. Mikhailidis. Cardiovascular effects of sodium–glucose cotransporter 2 inhibitors: multiple actions. Current Medical Research and Opinion 2016; 32(9) doi: 10.1080/03007995.2016.1201465
87
Lucia Pacifico, Enea Bonci, Gian Andreoli, Michele Di Martino, Alessia Gallozzi, Ester De Luca, Claudio Chiesa. The Impact of Nonalcoholic Fatty Liver Disease on Renal Function in Children with Overweight/Obesity. International Journal of Molecular Sciences 2016; 17(8) doi: 10.3390/ijms17081218
88
Emir Muzurović, Brigita Smolović, Snežana Vujošević, Milan Petakov. Editorial on Prevalence, Diagnosis and Treatment with 3 Different Statins of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?. Current Vascular Pharmacology 2021; 19(5) doi: 10.2174/1570161118666201008162537
89
Yu-Tao Zhan, Hai-Ying Su, Wei An. Glycosyltransferases and non-alcoholic fatty liver disease. World Journal of Gastroenterology 2016; 22(8): 2483-2493 doi: 10.3748/wjg.v22.i8.2483
90
Helena Katchman, Shira Zelber‐Sagi, Roni Baruch, Galia Berman, Idit F. Schwartz, Doron Schwartz, Richard Nakache, Yaacov Goykhman, Polina Katz, Oren Shibolet, Moshe Shashar, Ayelet Grupper. Progression and new onset of nonalcoholic fatty liver disease in living kidney donors compared to healthy controls. Clinical Transplantation 2018; 32(5) doi: 10.1111/ctr.13240
91
Mayur Virarkar, Janio Szklaruk, Corey T. Jensen, Melissa W. Taggart, Priya Bhosale. What's New in Hepatic Steatosis. Seminars in Ultrasound, CT and MRI 2021; 42(4) doi: 10.1053/j.sult.2021.03.001
92
Evelyn Nunes Goulart da Silva Pereira, Beatriz Peres de Araujo, Karine Lino Rodrigues, Raquel Rangel Silvares, Carolina Souza Machado Martins, Edgar Eduardo Ilaquita Flores, Caroline Fernandes-Santos, Anissa Daliry. Simvastatin Improves Microcirculatory Function in Nonalcoholic Fatty Liver Disease and Downregulates Oxidative and ALE-RAGE Stress. Nutrients 2022; 14(3) doi: 10.3390/nu14030716
93
Golnaz Ranjbar, Dimitri P. Mikhailidis, Amirhossein Sahebkar. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!. Metabolism 2019; 101 doi: 10.1016/j.metabol.2019.154001
94
Jake P. Mann, Paul Carter, Matthew J. Armstrong, Hesham K. Abdelaziz, Hardeep Uppal, Billal Patel, Suresh Chandran, Ranjit More, Philip N. Newsome, Rahul Potluri, Michael W. Greene. Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors. PLOS ONE 2020; 15(10) doi: 10.1371/journal.pone.0241357
95
Niki Katsiki, Christos Mantzoros. Making progress towards a better pathophysiological understanding and more promising therapeutic options for treating non-alcoholic steatohepatitis (NASH)/DASH (dysmetabolism associated steatohepatitis). Metabolism 2021; 114 doi: 10.1016/j.metabol.2020.154333
96
Daniel A Giles, Maria E Moreno-Fernandez, Traci E Stankiewicz, Simon Graspeuntner, Monica Cappelletti, David Wu, Rajib Mukherjee, Calvin C Chan, Matthew J Lawson, Jared Klarquist, Annika Sünderhauf, Samir Softic, C Ronald Kahn, Kerstin Stemmer, Yoichiro Iwakura, Bruce J Aronow, Rebekah Karns, Kris A Steinbrecher, Christopher L Karp, Rachel Sheridan, Shiva K Shanmukhappa, Damien Reynaud, David B Haslam, Christian Sina, Jan Rupp, Simon P Hogan, Senad Divanovic. Thermoneutral housing exacerbates nonalcoholic fatty liver disease in mice and allows for sex-independent disease modeling. Nature Medicine 2017; 23(7) doi: 10.1038/nm.4346
97
Mengzhen Dong, Shousheng Liu, Mengke Wang, Yifen Wang, Yongning Xin, Shiying Xuan. Relationship between AGT rs2493132 polymorphism and the risk of coronary artery disease in patients with NAFLD in the Chinese Han population. Journal of International Medical Research 2021; 49(7) doi: 10.1177/03000605211019263
98
Lars H. Breimer, Dimitri P. Mikhailidis. Does bilirubin protect against developing diabetes mellitus?. Journal of Diabetes and its Complications 2016; 30(4) doi: 10.1016/j.jdiacomp.2016.01.019
99
Yun Kyung Cho, Yu Mi Kang, Jee Hee Yoo, Jiwoo Lee, Seung Eun Lee, Dong Hyun Yang, Joon-Won Kang, Joong-Yeol Park, Chang Hee Jung, Hong-Kyu Kim, Woo Je Lee. The impact of non-alcoholic fatty liver disease and metabolic syndrome on the progression of coronary artery calcification. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-30465-y
100
Xin-yan Yu, Xiao-xiao Song, Yu-ling Tong, Ling-yan Wu, Zhen-ya Song. Usefulness of controlled attenuation parameter and liver stiffness measurement for detecting increased arterial stiffness in asymptomatic populations in China. Medicine 2020; 99(48) doi: 10.1097/MD.0000000000023360
101
Niki Katsiki, Dimitri P Mikhailidis, Maciej Banach. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease. Expert Opinion on Pharmacotherapy 2019; 20(16) doi: 10.1080/14656566.2019.1649394
102
Karolina Grąt, Michał Grąt, Olgierd Rowiński. Usefulness of Different Imaging Modalities in Evaluation of Patients with Non-Alcoholic Fatty Liver Disease. Biomedicines 2020; 8(9) doi: 10.3390/biomedicines8090298
103
Hritvik Jain, Neha Pervez, Debankur Dey, Fatima Ali Raza, Jyoti Jain, Mushood Ahmed, Aman Goyal, Ramez M. Odat, Mayank Jha, Muhammad Daoud Tariq, Sebastian Fox, Rukesh Yadav, Raheel Ahmed. Non-alcoholic fatty liver disease is associated with coronary flow reserve impairment: A pilot meta-analysis. Medicine 2024; 103(36) doi: 10.1097/MD.0000000000039499
104
Manca Povsic, On Yee Wong, Richard Perry, Juliana Bottomley. A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH). Advances in Therapy 2019; 36(7) doi: 10.1007/s12325-019-00960-3
105
Binayak Sinha, Debasis Datta, Samit Ghosal. Meta‐analysis of the effects of sodium glucose cotransporter 2 inhibitors in non‐alcoholic fatty liver disease patients with type 2 diabetes. JGH Open 2021; 5(2) doi: 10.1002/jgh3.12473
106
Niki Katsiki, Dimitri P Mikhailidis. Pioglitazone in patients with insulin resistance after ischemic stroke or transient ischemic attack: A comment on the IRIS trial. Journal of Diabetes and its Complications 2017; 31(1) doi: 10.1016/j.jdiacomp.2016.09.005
107
Jonathan M. Hazlehurst, Conor Woods, Thomas Marjot, Jeremy F. Cobbold, Jeremy W. Tomlinson. Non-alcoholic fatty liver disease and diabetes. Metabolism 2016; 65(8) doi: 10.1016/j.metabol.2016.01.001
108
Arrigo F G Cicero, Alessandro Colletti, Gani Bajraktari, Olivier Descamps, Dragan M Djuric, Marat Ezhov, Zlatko Fras, Niki Katsiki, Michel Langlois, Gustavs Latkovskis, Demosthenes B Panagiotakos, Gyorgy Paragh, Dimitri P Mikhailidis, Olena Mitchenko, Bernhard Paulweber, Daniel Pella, Christos Pitsavos, Željko Reiner, Kausik K Ray, Manfredi Rizzo, Amirhossein Sahebkar, Maria-Corina Serban, Laurence S Sperling, Peter P Toth, Dragos Vinereanu, Michal Vrablík, Nathan D Wong, Maciej Banach. Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Nutrition Reviews 2017; 75(9) doi: 10.1093/nutrit/nux047
109
Niki Katsiki, Panagiotis Anagnostis, Kalliopi Kotsa, Dimitrios G. Goulis, Dimitri P. Mikhailidis. Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus. Current Pharmaceutical Design 2019; 25(18) doi: 10.2174/1381612825666190708192134
110
Mohamad Kareem Marrache, Don C. Rockey. Statins for treatment of chronic liver disease. Current Opinion in Gastroenterology 2021; 37(3) doi: 10.1097/MOG.0000000000000716
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.